Across TCGA pan-cancer cohorts, ZAR1L Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ZAR1L data layer compared with 21 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher ZAR1L Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZAR1L expression acts as an unfavorable survival marker.

SARC are the cancer types where ZAR1L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.121	0.611	.041	6	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: ZAR1L tumor-vs-normal RNA expression · all ZAR1L data types